CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
Macrolane VRF 30device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00931268
NCT00931268N/ACompleted

Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With Stabilized Hyaluronic Acid of Non-animal Origin (Macrolane); a Baseline-controlled Single-centre Study.

Galderma R&D·interventional·Posted Jul 2, 2009·Updated Sep 28, 2022

In Brief

A clinical study evaluating Macrolane VRF 30 for Atrophy. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The study is being undertaken to establish the effectiveness and safety of Macrolane volume restoration factor 30 (VRF30) when used for treatment of HIV-infected subjects with buttocks lipoatrophy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrophy
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2, 2009
Enrollment StartAug 1, 2009
Primary CompletionSep 1, 2011
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17 years ago

Interventions

Macrolane VRF 30device

One administration